| Date | Title | Description |
| 21.05.2026 | Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting | 33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy
Durable responses, Treg reduction and increased CD8/Treg ratio support i... |
| 21.04.2026 | Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--AulosTM Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Pha... |
| 07.11.2025 | New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer | Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety profile easily managed in outpatient setting; ... |
| 03.10.2025 | Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 3, 2025 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today announced the presentation of updated Phase ... |
| 29.04.2025 | Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting | Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors
AU-007’s unique clinical activity includes CD8 effector T c... |
| 29.04.2025 | Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting | Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors
AU-007’s unique clinical activity includes CD8 effector T c... |
| 14.04.2025 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma | LARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina... |
| 14.04.2025 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma | LARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina... |
| 25.03.2025 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from the ... |
| 25.03.2025 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting | - |
| 27.11.2024 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer | - |
| 27.11.2024 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced dosing of the first patient with AU-007... |
| 07.11.2024 | Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Phase 1 and preliminary Phase 2 data for AU-007 with low-dose aldesleukin show clinical activity, durable Treg reduction and correlated progression-free survival
Melanoma and non-small cell lung cancer prioritized for further Phase 2 clinic... |
| 07.11.2024 | Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Phase 1 and preliminary Phase 2 data for AU-007 with low-dose aldesleukin show clinical activity, durable Treg reduction and correlated progression-free survival
Melanoma and non-small cell lung cancer prioritized for further Phase 2 clinic... |
| 23.10.2024 | Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | AU-007 demonstrates continued distinction in IL-2 class, with unique profile of Treg reduction and correlated longer PFS outcomes, coupled with increases in tumor-killing Teffs
Phase 2 clinical efficacy and safety data to be presented befor... |
| 23.10.2024 | Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | AU-007 demonstrates continued distinction in IL-2 class, with unique profile of Treg reduction and correlated longer PFS outcomes, coupled with increases in tumor-killing Teffs
Phase 2 clinical efficacy and safety data to be presented befor... |
| 09.10.2024 | Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced that pharmacokinetic data for evaluatio... |
| 09.10.2024 | Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced that pharmacokinetic data for evaluatio... |
| 04.10.2024 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 4, 2024 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of continued promisin... |
| 04.10.2024 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 4, 2024 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of continued promisin... |
| 23.05.2024 | Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting | Preliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed through checkpoint inhibitors
The results confirm the ability of AU-007, ... |
| 23.05.2024 | Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting | Preliminary results show durable anti-tumor activity in multiple solid tumor types among heavily pre-treated patients, including patients whose tumors have progressed through checkpoint inhibitors
The results confirm the ability of AU-007, ... |
| 15.05.2024 | Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007 | Combination of novel IL-2 therapeutic AU-007, Bavencio® (avelumab) and aldesleukin in Phase 2 cohort of AU-007 clinical trial to build on compelling preclinical evidence of eradication of solid tumors
LARKSPUR, Calif., May 15, 2024 – Aulos ... |
| 15.05.2024 | Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007 | Combination of novel IL-2 therapeutic AU-007, Bavencio® (avelumab) and aldesleukin in Phase 2 cohort of AU-007 clinical trial to build on compelling preclinical evidence of eradication of solid tumors
LARKSPUR, Calif., May 15, 2024 – Aulos ... |
| 24.04.2024 | Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-... |
| 24.04.2024 | Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting | - |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | Preliminary Phase 2 data in melanoma, renal cell carcinoma anticipated to be presented by mid-2024
LARKSPUR, Calif. (BUSINESS WIRE) -- Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the developmen... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | - |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-treated patients and well-tolerated safety profile
Phase 2 portion to assess AU-007 in combination with low-dose Proleukin®, with initial expan... |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including those whose tumors progressed through checkpoint inhibitors
Further development of AU-007 to continue in combination with low-dose aldesleukin,... |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuti... | Interim data from an ongoing trial support overall mechanism of action of AU-007, a computationally designed human monoclonal antibody, in decreasing Tregs while increasing effector T cells and NK cells
Clinical efficacy and safety data fr... |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic... | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced the presentation of encouraging pha... |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that new safety and efficacy data f... |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners | Funds from ATP will continue to sustain the progress of Aulos’ novel IL-2 therapeutic AU-007 through a Phase 2 trial in solid tumor cancers
The additional funding is substantiated by interim data from Aulos’ ongoing Phase 1/2 trial release... |
| 01.08.2023 | Aulos Bioscience Raises $20M in Series A Extension Financing | Aulos Bioscience, a Larkspur, CA-based immuno-oncology company, raised $20m in Series A extension funding.
Apple Tree Partners (ATP) made the investment.
The company intends to use the funds to advance its lead human monoclonal antibody can... |
| 01.08.2023 | Aulos Bioscience Lands $20M Series A Extension |
LARKSPUR, CA, Aulos Bioscience today announced $20 million in Series A extension funding committed by Apple Tree Partners.
>> Click here for more funding data on Aulos Bioscience
>> To export Aulos Bioscience funding data to... |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners | - |
| 25.05.2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class
Initial anti-tumor activity has been observ... |
| 01.02.2023 | First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors | Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S.
U.S. enrollment begins in North Carolina, with additional sites being planned nationwide
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Biosci... |
| 10.11.2022 | Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting | Data show trend in decreasing Tregs, presenting unique profile among current IL-2 therapeutics
Adding Phase 1/2 clinical trial sites in the U.S. following recent IND application clearance
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscienc... |
| 31.10.2022 | Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors | AU-007 represents the company’s first program to receive IND clearance
Expansion of Phase 1/2 clinical study into the U.S. marks major milestone for first-ever human trial of a computationally designed human monoclonal antibody for cancer ... |
| 12.10.2022 | Ascidian Therapeutics Launches to Rewrite RNA | ATP incubated and built Ascidian with $50 million in Series A funding
Pioneering RNA exon editing platform expands therapeutic possibilities to treat diseases not addressed by today’s gene editing technologies
Lead program targeting ABCA4... |
| 11.10.2022 | Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that initial safety data from patie... |
| 26.05.2022 | Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting | Trials in Progress poster describes design of recently initiated Phase 1/2 study of AU-007 for treatment of solid tumors
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care t... |
| 05.05.2022 | Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors | Clinical program advancement represents key milestone for Aulos as a clinical-stage company and AU-007’s potential as a novel cancer treatment
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revol... |
| 27.04.2022 | Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that a poster describing the design... |
| 21.03.2022 | Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors | Data show significant tumor growth inhibition with AU-007, a computationally designed, human IgG1 monoclonal antibody, and complete tumor eradication when dosed in combination with checkpoint inhibitors
Phase 1/2 clinical trial planning in... |
| 21.03.2022 | Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors | Data show significant tumor growth inhibition with AU-007, a computationally designed, human IgG1 monoclonal antibody, and complete tumor eradication when dosed in combination with checkpoint inhibitors |
| 23.02.2022 | Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007 | New data demonstrate eradication of solid tumors in preclinical study
LARKSPUR, Calif., February 23, 2022 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-cl... |
| 12.11.2021 | Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting | Data support ability of AU-007, a computationally evolved, human IgG1 monoclonal antibody, to specifically block IL-2’s binding to CD25 and inhibit tumor growth in multiple cancer models
Data show potential of novel cancer treatment to bre... |
| 05.10.2021 | Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through a potentially best-in-class, computationally evolved IL-2 human antibody, today announced the planned presentation ... |
| 14.06.2021 | Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer | LARKSPUR, Calif., June 14, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, has appointed Jim Vasselli, ... |
| 14.06.2021 | Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer | LARKSPUR, Calif., June 14, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, has appointed Jim Vasselli, ... |
| 17.05.2021 | Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer | LARKSPUR, Calif., May 17, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redm... |
| 17.05.2021 | Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer | LARKSPUR, Calif., May 17, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redm... |
| 30.03.2021 | Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors | BOSTON and TEL AVIV, Israel, March 30, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today ... |
| 30.03.2021 | Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors | BOSTON and TEL AVIV, Israel, March 30, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today ... |
| 15.03.2021 | Aulos Bioscience Appoints Aron Knickerbocker as CEO | BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announce... |
| 15.03.2021 | Aulos Bioscience Appoints Aron Knickerbocker as CEO | BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announce... |
| 12.01.2021 | Daily funding roundup - January 11th, 2021 | Aulos Bioscience has raised $40M; Komodo Health landed $44M; EQRx secured $500M
Hello Ralphie: Hello Ralphie is a New York-based veterinary telemedicine company. Hello Ralphie raised $1 million in seed funding from HearstLab and WPMC Fund. ... |
| 08.01.2021 | Aulos raises $40M to unlock the anti-cancer power of IL-2
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | ATP and Biolojic Design have teamed up to create IL-2-focused cancer biotech Aulos Bioscience. The startup begins life with IL-2-binding monoclonal antibodies designed by Biolojic Design and a $40 million funding commitment from ATP, positi... |
| 08.01.2021 | Aulos raises $40M to unlock the anti-cancer power of IL-2 | ATP and Biolojic Design have teamed up to create IL-2-focused cancer biotech Aulos Bioscience. The startup begins life with IL-2-binding monoclonal antibodies designed by Biolojic Design and a $40 million funding commitment from ATP, positi... |
| 08.01.2021 | ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer | Immuno-oncology spinout from Biolojic Design created with $40M Series A financing from ATP
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON and TEL AVIV, January 8, 2021/PR NEWSWIRE/ – ATP, a leading... |
| 08.01.2021 | ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer | Immuno-oncology spinout from Biolojic Design created with $40M Series A financing from ATP |
| - | Aulos Bioscience | “Aulos Bioscience is a immuno-oncology company revolutionizing cancer care through the development of best-in-class IL-2 therapeutics. Learn more.” |
